MX2023003035A - Compuestos como moduladores de bis-fosfoglicerato mutasa para el tratamiento de la anemia de celulas falciforme. - Google Patents
Compuestos como moduladores de bis-fosfoglicerato mutasa para el tratamiento de la anemia de celulas falciforme.Info
- Publication number
- MX2023003035A MX2023003035A MX2023003035A MX2023003035A MX2023003035A MX 2023003035 A MX2023003035 A MX 2023003035A MX 2023003035 A MX2023003035 A MX 2023003035A MX 2023003035 A MX2023003035 A MX 2023003035A MX 2023003035 A MX2023003035 A MX 2023003035A
- Authority
- MX
- Mexico
- Prior art keywords
- bis
- compounds
- modulators
- sickle cell
- treatment
- Prior art date
Links
- 102100036200 Bisphosphoglycerate mutase Human genes 0.000 title abstract 3
- 108010029692 Bisphosphoglycerate mutase Proteins 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 208000007056 sickle cell anemia Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se proporcionan en la presente compuestos y composiciones de los mismos para modular la bis-fosfoglicerato mutasa (BPGM) y tratar las células de anemia falciforme.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063077973P | 2020-09-14 | 2020-09-14 | |
| PCT/US2021/050216 WO2022056449A1 (en) | 2020-09-14 | 2021-09-14 | Compounds as modulators of bis-phosphoglycerate mutase for the treatment of sickle cell disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023003035A true MX2023003035A (es) | 2023-06-06 |
Family
ID=78080554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023003035A MX2023003035A (es) | 2020-09-14 | 2021-09-14 | Compuestos como moduladores de bis-fosfoglicerato mutasa para el tratamiento de la anemia de celulas falciforme. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230348454A1 (es) |
| EP (1) | EP4210825A1 (es) |
| JP (1) | JP2023541152A (es) |
| CN (1) | CN116406361A (es) |
| AU (1) | AU2021339844A1 (es) |
| BR (1) | BR112023004329A2 (es) |
| CA (1) | CA3194198A1 (es) |
| CL (1) | CL2023000721A1 (es) |
| CO (1) | CO2023003078A2 (es) |
| CR (1) | CR20230157A (es) |
| DO (1) | DOP2023000051A (es) |
| EC (1) | ECSP23019537A (es) |
| IL (1) | IL301169A (es) |
| MX (1) | MX2023003035A (es) |
| PE (1) | PE20240213A1 (es) |
| WO (1) | WO2022056449A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117886810A (zh) * | 2023-12-18 | 2024-04-16 | 徐州医科大学 | 一种吲哚啉类化合物及其制备方法和应用 |
| US20250304535A1 (en) * | 2024-03-29 | 2025-10-02 | Beigene Switzerland Gmbh | KAT6 Inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60222804T2 (de) * | 2001-12-21 | 2008-07-03 | Vernalis (Cambridge) Ltd., Abington | 3-(2,4)dihydroxyphenyl-4-phenylpyrazole und deren medizinische verwendung |
| AR044519A1 (es) * | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
| GB0524814D0 (en) * | 2005-12-05 | 2006-01-11 | Glaxo Group Ltd | Compounds |
| JP2009524591A (ja) * | 2005-12-21 | 2009-07-02 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャネルのモジュレーターとしての複素環誘導体 |
| PE20091953A1 (es) * | 2008-05-08 | 2010-01-09 | Du Pont | Azoles sustituidos como fungicidas |
| CN107266433A (zh) * | 2010-11-09 | 2017-10-20 | 铁木医药有限公司 | sGC刺激剂 |
| CN103965167A (zh) * | 2013-01-29 | 2014-08-06 | 通化济达医药有限公司 | 咪唑羧酸衍生物 |
| WO2018151830A1 (en) * | 2017-02-17 | 2018-08-23 | Fronthera U.S. Pharmaceuticals Llc | Pyridinyl based apoptosis signal-regulation kinase inhibitors |
| CN113260609A (zh) * | 2018-09-04 | 2021-08-13 | 美真达治疗公司 | 芳烃受体拮抗剂及其使用方法 |
-
2021
- 2021-09-14 EP EP21787221.7A patent/EP4210825A1/en active Pending
- 2021-09-14 JP JP2023516062A patent/JP2023541152A/ja active Pending
- 2021-09-14 CA CA3194198A patent/CA3194198A1/en active Pending
- 2021-09-14 IL IL301169A patent/IL301169A/en unknown
- 2021-09-14 US US18/025,853 patent/US20230348454A1/en active Pending
- 2021-09-14 WO PCT/US2021/050216 patent/WO2022056449A1/en not_active Ceased
- 2021-09-14 PE PE2023001161A patent/PE20240213A1/es unknown
- 2021-09-14 AU AU2021339844A patent/AU2021339844A1/en active Pending
- 2021-09-14 MX MX2023003035A patent/MX2023003035A/es unknown
- 2021-09-14 CN CN202180076111.9A patent/CN116406361A/zh active Pending
- 2021-09-14 BR BR112023004329A patent/BR112023004329A2/pt unknown
- 2021-09-14 CR CR20230157A patent/CR20230157A/es unknown
-
2023
- 2023-03-13 DO DO2023000051A patent/DOP2023000051A/es unknown
- 2023-03-14 CO CONC2023/0003078A patent/CO2023003078A2/es unknown
- 2023-03-14 CL CL2023000721A patent/CL2023000721A1/es unknown
- 2023-03-16 EC ECSENADI202319537A patent/ECSP23019537A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021339844A9 (en) | 2024-04-18 |
| WO2022056449A1 (en) | 2022-03-17 |
| JP2023541152A (ja) | 2023-09-28 |
| IL301169A (en) | 2023-05-01 |
| CL2023000721A1 (es) | 2023-10-30 |
| CA3194198A1 (en) | 2022-03-17 |
| US20230348454A1 (en) | 2023-11-02 |
| CR20230157A (es) | 2023-07-13 |
| DOP2023000051A (es) | 2023-07-16 |
| AU2021339844A1 (en) | 2023-05-04 |
| ECSP23019537A (es) | 2023-06-30 |
| CO2023003078A2 (es) | 2023-04-27 |
| BR112023004329A2 (pt) | 2023-04-04 |
| PE20240213A1 (es) | 2024-02-16 |
| CN116406361A (zh) | 2023-07-07 |
| EP4210825A1 (en) | 2023-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551934A1 (en) | Magl inhibitors | |
| MX2021013193A (es) | Cicloalquilos sustituidos como moduladores de la vía integrada del estrés. | |
| GEP20247708B (en) | Cystic fibrosis transmembrane conductance regulator modulating agents | |
| CO2020010552A2 (es) | Compuestos | |
| PH12021552759A1 (en) | Substituted cycloalkyls as modulators of the integrated stress pathway | |
| MY207223A (en) | Prodrug modulators of the integrated stress pathway | |
| MX2020002806A (es) | Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso. | |
| MX2023005928A (es) | Moduladores de malt-1. | |
| WO2019090085A8 (en) | Modulators of the integrated stress pathway | |
| BR112022023025A2 (pt) | Moduladores de htt para tratar doença de huntington | |
| EP4338804A3 (en) | Epinephrine spray formulations | |
| EA202191519A1 (ru) | Модуляторы trex1 | |
| MX2021007948A (es) | Inhibidores de proteina de activacion de fibroblastos. | |
| MX2023008589A (es) | Compuestos moduladores de gcn2 y usos de los mismos. | |
| ZA202301275B (en) | Indole compounds as androgen receptor modulators | |
| MX2023003035A (es) | Compuestos como moduladores de bis-fosfoglicerato mutasa para el tratamiento de la anemia de celulas falciforme. | |
| MX2018008903A (es) | COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA. | |
| MX2023001296A (es) | Composiciones y metodos para tratar enfermedades y trastornos. | |
| MX2023004942A (es) | Compuestos biciclicos y usos de los mismos para el tratamiento de enfermedades. | |
| PH12020552172A1 (en) | Cyclic dinucleotides as sting agonists | |
| PH12022550497A1 (en) | Perk inhibiting compounds | |
| MX2024004416A (es) | Nuevos moduladores de ehmt1 y ehmt2 y uso terapéutico de estos. | |
| SA521431274B1 (ar) | مشتق تتراهيدرو إيزوكينولين بديل كمعدِّل تفارغي إيجابي d1 | |
| MX2022003816A (es) | Compuestos antibacterianos. | |
| MX2022003814A (es) | Compuestos antibacterianos de 4-quinolinona. |